Two mutant virus strains in which the novel P225H mutation appeared in a V106A reverse transcriptase (RT)-mutated genetic background upon treatment of human immunodeficiency virus type 1 (HIV-1) with quinoxaline S-2720 were isolated. Surprisingly, the addition of the P225H mutation to the V106A RT mutant genetic background resensitized the V106A RT mutant virus to the nonnucleoside RT inhibitor (NNRTI) BHAP U-90152, but not to other NNRTIs. Construction of both recombinant viruses and recombinant RTs containing the V106A, P225H and V106AM P225H mutations revealed that P225H was indeed responsible for the marked potentiation of the antiviral activity of BHAP against the P225H single-mutant virus and the V106AM P225H double-mutant virus when compared to wild-type and V106A single-mutant viruses, respectively. An explanation for the markedly increased sensitivity of the P225H mutant HIV-1 RT to BHAP and not to the other NNRTIs was provided by the unique features of the X-ray structure of the RT-BHAP complex.
Two mutant virus strains in which the novel P225H mutation appeared in a V106A reverse transcriptase (RT)-mutated genetic background upon treatment of human immunodeficiency virus type 1 (HIV-1) with quinoxaline S-2720 were isolated. Surprisingly, the addition of the P225H mutation to the V106A RT mutant genetic background resensitized the V106A RT mutant virus to the nonnucleoside RT inhibitor (NNRTI) BHAP U-90152, but not to other NNRTIs. Construction of both recombinant viruses and recombinant RTs containing the V106A, P225H and V106AM P225H mutations revealed that P225H was indeed responsible for the marked potentiation of the antiviral activity of BHAP against the P225H single-mutant virus and the V106AM P225H double-mutant virus when compared to wild-type and V106A single-mutant viruses, respectively. An explanation for the markedly increased sensitivity of the P225H mutant HIV-1 RT to BHAP and not to the other NNRTIs was provided by the unique features of the X-ray structure of the RT-BHAP complex.
The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is an important target enzyme for the chemotherapy of AIDS because of its key role in virus replication (De Clercq, 1995 a, b) . The non-nucleoside RT inhibitors (NNRTIs) represent a wide range of highly specific inhibitors of HIV-1 RT. Although the NNRTIs are potent HIV-1 inhibitors endowed with low toxicity, their clinical use has been questioned owing to the rapid emergence of drugresistant virus variants (De Clercq, 1994 ; Schinazi et al., 1996) . Drug resistance to NNRTIs is primarily associated with mutations of amino acids that surround the lipophilic NNRTIAuthor for correspondence : Jan Balzarini.
Fax j32 16 337340. e-mail Jan.Balzarini!rega.kuleuven.ac.be specific binding pocket of the RT. Often, appearance of these mutations results in cross-resistance to other NNRTIs, thus aggravating the resistance problem.
P225 is one of the amino acids forming the mouth of the hydrophobic NNRTI-specific binding pocket of HIV-1 RT, and is highly conserved in the RTs of HIV-1, HIV-2 and simian immunodeficiency virus (SIV). Hizi & Shaharabany (1992) have studied the role of the P225-P226 and P419-P420 amino acid pairs (the only two sets of highly conserved double prolines) in the proper folding of the enzymatic domains of HIV-1 RT. Palaniappan et al. (1997) have investigated the role of each of the amino acids from positions 224-235, which span the primer grip region of RT, for their effect on RNase H function. Interestingly, none of the P225 mutations that were examined in these studies had any effect on the catalytic activity of HIV-1 RT.
Recently, we described two mutant virus strains in which a P225H mutation had appeared in a V106A RT-mutated genetic background upon treatment of HIV-1 with dose-escalating concentrations of quinoxaline S-2720 (Pelemans et al., 1997) . Addition of the P225H mutation to the V106A mutant led to a virus with a relatively small increase in resistance to most NNRTIs, the largest increase in resistance (approx. 12-fold) being to . Surprisingly, addition of the P225H to the V106A mutation led to resensitization to the NNRTI BHAP U-90152 relative to the V106 mutant (Pelemans et al., 1997) .
Since we did not detect a P225H singly mutated HIV-1 strain in our selection experiments, we have now constructed four recombinant mutant viruses, including the wild-type, the V106A, the P225H and the V106AjP225H mutant viruses, to determine the contribution of the P225H, the V106A and the paired V106AjP225H mutations to the resistance pattern against NNRTIs. Recombinant viruses have the advantage that they share a common genetic background, and therefore any effect on inhibitor binding and RT catalytic activity can be unambiguously associated with a well-defined mutation in the RT. The recombinant V106A, P225H and V106AjP225H mutant viruses were constructed using a slight modification of the recombinant virus assay described by Kellam & Larder (2n2) 0n036 (2n6\4n2) (1994). They were obtained through homologous recombination of RT with RT-deleted proviral DNA that was propagated in pHIV∆RTBstEII (Kellam & Larder, 1994) . The RT used in the recombination was the NcoI-HindIII fragment from pKRT2 (D'Aquila & Summers, 1989) . Mutations were introduced in pKRT2 using the Altered Sites in vitro mutagenesis system from Promega (Pelemans et al., 1997) . MT4 cells were electroporated with approximately 2 µg RT DNA and approximately 10 µg pHIV∆RTBstEII DNA. Upon successful homologous recombination, viable recombinant virus could be recovered from the cell cultures. The presence of the V106A and P225H mutations was checked by sequencing of the virus DNA samples on an Automated Laser Fluorescent (ALF) DNA sequencer using the Autoread T7 sequencing kit from Pharmacia as described previously (Schmit et al., 1996 a, b) . The recombinant mutant viruses were evaluated for their sensitivities to representative members of the different classes of NNRTIs (Table 1 ). The EC &! was determined as described previously (Balzarini et al., 1991) .
The majority of the NNRTIs, i.e. MKC-442, BHAP U-90152 (delavirdine), 9-chloro-TIBO, quinoxaline S-2720 and thiocarboxanilide UC-781, showed a 17-30-fold decrease of inhibitory activity against the recombinant V106A mutant virus. The quinoxaline HBY 097 lost only 13-fold of its inhibitory activity, whereas the antiviral potency of pyridinone L-697,661 was only slightly affected (approx. 2-fold) by the V106A mutation. The P225H mutation in the recombinant HIV-1 resulted in only 2-6-fold decreases of sensitivity to all NNRTIs tested, except for BHAP U-90152, where there was actually a 2n5-fold increase in sensitivity (Table 1) . The V106AjP225H recombinant double mutant showed highlevel resistance against , quinoxaline S-2720 (125-fold), quinoxaline HBY 097 (140-fold), thiocarboxanilide UC-781 (129-fold) and 9-chloro-TIBO (73-fold). Whereas BHAP U-90152 showed 20-fold reduced activity against the V106A recombinant mutant virus, the doublemutant recombinant virus was only 4n2-fold less sensitive to BHAP U-90152 compared to wild-type. This may be ascribed to compensation of V106A resistance by the hypersensitivity conferred by the P225H RT mutation. Thus, through the construction of recombinant mutant viruses, we demonstrate unambiguously that the remarkable resensitization of the V106AjP225H double-mutant virus to BHAP U-90152 is due solely to the presence of the P225H mutation (Table 1) .
We found a strong correlation (r l 0n88-0n96) when the EC &! values against the different NNRTIs of the recombinant mutant RT viruses described here were compared with the EC &! values of the V106A and V106AjP225H RT mutant viruses obtained through dose-escalating treatment of HIV-1(IIIB) with quinoxaline S-2720 in cell culture (Pelemans et al., 1997) (Fig. 1) . Thus, antiviral data obtained with the mutant recombinant viruses fully agree with the antiviral data obtained with the resistant virus strains that appeared upon selection in the presence of quinoxaline S-2720 in cell culture. Furthermore, there is a strong correlation between the EC &! values against the P225H recombinant virus and the IC &! values against the P225H recombinant RT for the different NNRTIs (r l 0n93 ; data not shown).
We have also constructed the relevant mutant recombinant RTs and examined the inhibitory activity of NNRTIs against the V106A, P225H and V106AjP225H recombinant mutant RTs using different template\primers (Table 2) . Recombinant RT was purified using a modification of the rapid high-pressure liquid chromatography method described by Fletcher et al. (1996) . Briefly, 500 ml cultures of E. coli JM109 harbouring BDEI P225H sensitizes HIV-1 RT to BHAP U-90152 P225H sensitizes HIV-1 RT to BHAP U-90152 11 (16) 275 (64) 0n57 (25) 1n3 (12) 5n3 (21) 0n71 (0n7) 0n16 P225H 0n09 (0n1) 12 (2n8) 0n074 (3n2) 0n80 (7n3) 0n67 (2n7) 8n9 (13) 244 (42) 2n3 (15) 1n3 (11) 9n3 (12) 0n92 (0n8) 0n06 P225H 0n28 (0n4) 7n5 (1n3) 0n51 (3n4) 0n60 (5n0) 2n4 (3n0) 3n4 (3n0) 0n03 V106AjP225H 8n9 (13\5n2) 679 (118\55) 20 (134\51) 26 (219\55) 52 (68\36) 2n2 (1n9\2n4) 0n07 Poly(I).oligo(dC [12] [13] [14] [15] [16] [17] [18] ) ddCTP Wild-type 7n2 7 6 0 n 14 1n0 4 n 6 8 n 9 4 n 78 V106A
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57 (8) 1105 (15) 2n6 (19) 9n7 (9n7) 47 (10) 1n3 (0n2) 3n23 P225H 0n70 (0n1) 116 (1n5) 0n54 (3n9) 4n1 (4n1) 9n4 (2n0) Pelemans et al. (1997). pKRT2, pKRT2(V106A), pKRT2(P225H) or pKRT2(V106A\ P225H) were grown at 37 mC and induced with IPTG for the expression of the p66 form of RT. The cells were harvested and lysed using the lysozyme-DNase I protocol described by Sambrook et al. (1989) . The clarified lysates were applied onto columns of DEAE-Sephacel (Pharmacia) and the flowthrough and washes were combined, concentrated, incubated at 4 mC overnight to allow ' processing ' of the p66 RT to the p66\p51 heterodimer, and then brought onto an Econo-PacS cartridge (Bio-Rad). The RT was eluted from the S column with a linear NaCl gradient (0-250 mM) and stored at k80 mC. The IC &! was determined as described previously (Balzarini et al., 1992) . A fixed concentration of the labelled substrate [2,8-$H]dGTP (sp. act. 3n6 Ci\mmol) (5n6 µM, 1 µCi), [5-$H]dCTP (sp. act. 18n9 Ci\mmol) (1n06 µM, 1 µCi) and [methyl-$H]dTTP (sp. act. 51 Ci\mmol) (0n37 µM, 1 µCi) and a fixed concentration of the template\primers poly(C).oligo(dG "# -") ) (0n1 mM), poly-(I).oligo(dC "# -") ) (15 µM, 3n75 µM), poly(A).oligo(dT "# -") ) (15 µM, 3n75 µM) were used.
The mutant recombinant RTs showed the same resistance pattern against the NNRTIs as the corresponding recombinant mutant viruses, regardless of the nature of the template\primer ( Table 2 ). The P225H mutation showed a pronounced increase in sensitivity against BHAP U-90152 [8-10-fold for poly(C).oligo(dG "# -") ) and poly(I).oligo(dC "# -") ), and 3-fold for poly(A).oligo(dT "# -") )]. Moreover, the P225H mutation also compensated for the decrease in sensitivity caused by the V106A mutation. This resulted in wild-type sensitivity of the V106AjP225H double-mutant recombinant RT against BHAP U-90152. Thus, data obtained from the mutant recombinant RTs were in full agreement with the sensitivity\ resistance data obtained for the mutant recombinant viruses. The pyridinone L-697,661 proved not less inhibitory to the V106A mutant enzyme than to wild-type RT, and this was also reflected in the sensitivity of the V106A mutant recombinant viruses to pyridinone (Tables 1 and 2 ). Further analysis of the effects of the individual mutations, V106A and P225H, on resistance to the different NNRTIs revealed that they were not merely additive. Indeed, we observed a slight, but consistent, potentiation of the degree of resistance afforded by the P225H mutation when combined with the V106A mutation (Tables 1 and 2 ). [Compare the experimental values with the calculated (expected) values.] The experimentally found resistance values proved consistently higher than the calculated resistance values except for BHAP U-90152, and to a lesser extent, pyridinone L-697,661, where a more pronounced sensitization was observed.
To investigate the structural basis for the effect of these mutations, a model for the pyridinone L-697,661 complex with RT ( Fig. 1 D) was created based on the structure of the complex between RT and MKC-442 (Hopkins et al., 1996) . This could then be compared with X-ray and modelled structures of the BDFA P225H sensitizes HIV-1 RT to BHAP U-90152 P225H sensitizes HIV-1 RT to BHAP U-90152 other RT-NNRTI complexes. The greater sensitivity of the P225H recombinant mutant virus and P225H recombinant mutant RT to BHAP U-90152 is in full agreement with the structure of the RT-BHAP complex determined by X-ray crystallography (Fig. 1 D ; Esnouf et al., 1997) . When BHAP U-90152 binds to HIV-1 RT, the methylsulphonamide moiety protrudes into the solvent creating a channel between P236 and the polypeptide segments 225-226 and 105-106. To accommodate this, the main chain near P225 has to swing around by approximately 180m, leaving P225 exposed on the surface of the enzyme. Thus, a change from proline to a more hydrophilic residue such as histidine is likely to stabilize the RT-BHAP complex, thereby resulting in an increased sensitivity of the P225H mutant virus and P225H mutant RT to BHAP U-90152. For MKC-442, and other HEPT analogues, the shortest interatomic distances between P225 and each inhibitor are 7-8 A H , whereas for the complexes with thiocarboxanilide UC-781 (modelled structure), 9-chloro-TIBO (Xray structure) and pyridinone L-697,661 (modelled structure) the minimum distances are 12-15 A H . Thus, the effect of the P225H mutation decreased with increasing separation of residue 225 and the NNRTI.
Residue V106 is involved in numerous minor hydrophobic stabilizing interactions with most NNRTIs. The loss of this stabilization due to the smaller side chain of the V106A mutant may increase the off-rate of the inhibitors, conferring resistance. In our model for the RT complex with pyridinone L-697,661 (Fig. 1 D) , there are relatively few interactions between V106 and the inhibitor (only with the 5-ethyl group) and so the effect on off-rate may be smaller than for the other NNRTIs studied.
Our finding that the P225H mutation in HIV-1 RT leads to a sensitization of the mutant enzyme (and the corresponding mutant virus) to BHAP U-90152 is the second example of an amino acid mutation selected in the presence of one NNRTI that sensitizes the RT to other NNRTIs. Dueweke et al. (1993) have demonstrated that BHAP U-90152 can select for a P236L mutation which has marked resistance to BHAP, but significantly increased sensitivity to other NNRTIs. The amino acid mutation reported in this study emerged under selective drug pressure of quinoxaline S-2720. It gave moderate resistance to most NNRTIs, but remarkable sensitivity to one particular NNRTI (BHAP U-90152). We have been able to offer a molecular explanation for this phenomenon (Pelemans et al., 1997 ; Esnouf et al., 1997 ; and this study) based on crystallographic and modelling studies of the NNRTIs in complex with HIV-1 RT.
In conclusion, we have demonstrated through construction of recombinant mutant virus strains and site-directed mutagenesis of recombinant HIV-1 RT that a single mutation at amino acid position 225 in the HIV-1 RT is responsible for the marked hypersensitivity of the P225H mutant virus to BHAP U-90152. Moreover, the presence of the P225H as an additional mutation in a V106A mutant RT genetic background proved able to lower markedly the degree of phenotypic resistance of the V106A mutant RT and virus to BHAP U-90152.
